Antiretroviral
            <scp>drug–drug</scp>
            interactions: A comparison of online drug interaction databases

Drwiega, Emily N; Badowski, Melissa E; Michienzi, Sarah M

doi:10.1111/jcpt.13750

Cited by 8 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the reporting of real-world DDI data to www.clinicalcasesDDIs.com is highly encouraged as it serves as a valuable resource for assessing the clinical relevance of DDIs. This becomes particularly crucial given the occasionally theoretical and conflicting information present in available electronic databases [6,19]. Documenting real-world cases helps bridge knowledge gaps, ultimately enhancing the quality of care for PWH.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study

Ambrosioni,

Díaz,

Marzolini

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

Introduction The objective was to characterize real-world outcomes of drug–drug interactions (DDIs) between antiretrovirals (ARVs) and other drugs, including over-the-counter medications (OTC), and treatment outcomes in clinical practice. Methods www.clinicalcasesDDIs.com is an open-access website for healthcare providers to consult and briefly describe real-world clinical cases on DDI with ARVs. We reviewed all the clinical cases reported to the website between March 2019 and May 2023. Results A total of 139 cases were reported, mostly involving ritonavir or cobicistat (boosters; 74 cases), unboosted integrase inhibitors (InSTI; 29 cases), and non-nucleoside reverse transcriptase inhibitors (NNRTI; 23 cases). Central nervous system drugs (29 cases) and cardiovascular drugs (19 cases) were the most frequently described co-medications. Notably, OTC medications were implicated in 27 cases, including mineral supplements (11 cases), herbals (8 cases), weight loss drugs (4 cases), anabolic steroids (3 cases), and recreational drugs (1 case). OTC acted as the perpetrator drug in 21 cases, leading to loss of ARV efficacy in 17 instances (mineral supplements in 10 cases, weight loss drugs in 4 cases, herbals in 3 cases). Additionally, toxicity was reported in 4 out of 6 cases where OTC was considered the victim drug of the DDI (anabolic steroids in 3 cases, MDMA in 1 case). Conclusions Frequent unwanted outcomes resulting from DDIs between ARVs and OTC medications underscore the importance of integrating non-prescription drugs into medication reconciliation. The real-world data available through www.clinicalcasesDDIs.com serves as a valuable resource for assessing the clinical relevance of DDIs.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Consequently, the clinical significance of many DDIs remains uncertain. Furthermore, discrepancies on the relevance of a particular DDI may be found between different databases, further complicating the interpretation of a given potential interaction [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study

Ambrosioni,

Díaz,

Marzolini

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

show abstract

“…Most notably, a similar recent study found that Micromedex had among the highest scores for scope and completeness looking at information for off-label uses and infectious disease information [ 13 , 25 ]. Conversely, compared to Clinical Pharmacology and Lexicomp, Micromedex reported fewer drug-drug interactions for assessed antiviral medications in a recent study [ 26 ]. These results, in combination with assessment of user needs and other comparable resources in the collection, will assist health sciences librarians in assessing the appropriateness of continued support of Micromedex despite price increases.…”

Section: Discussionmentioning

confidence: 99%

Tertiary drug information sources for treatment and prevention of COVID-19

Beckett,

Brattain,

Truong

et al. 2023

jmla

View full text Add to dashboard Cite

Objective: To evaluate tertiary drug information databases in terms of scope, consistency of content, and completeness of COVID-19 drug information. Methods: Five electronic drug information databases: Clinical Pharmacology, Lexi-Drugs, AHFS DI (American Hospital Formulary Service Drug Information), eFacts and Comparisons, and Micromedex In-Depth Answers, were evaluated in this cross-sectional evaluation study, with data gathered from October 2021 through February 2022. Two study investigators independently extracted data (parallel extraction) from each resource. Descriptive statistics were primarily used to evaluate scope (i.e., whether the resource addresses use of the medication for treatment or prevention of COVID-19) and completeness of content (i.e., whether full information is provided related to the use of the medication for treatment or prevention of COVID-19) based on a 10-point scale. To analyze consistency among resources for scope, the Fleiss multi-rater kappa was used. To analyze consistency among resources for type of recommendation (i.e., in favor, insufficient evidence, against), a two-way mixed effects intraclass coefficient was calculated. Results: A total of 46 drug monographs, including 3 vaccination monographs, were evaluated. Use of the agents for treatment of COVID-19 was most frequently addressed in Lexi-Drugs (73.9%), followed by eFacts and Comparisons (71.7%), and Micromedex (54.3%). The highest overall median completeness score was held by AHFS DI followed by Micromedex, and Clinical Pharmacology. There was moderate consistency in terms of scope (kappa 0.490, 95% CI 0.399-0.581, p<0.001) and recommendations (intraclass correlation coefficient 0.518, 95% CI 0.385-0.651, p<0.001).

show abstract

“…Although multiple drug interaction-support web resources are available (including but not limited to LexiComp, Clinical Pharmacology, Micromedex, Liverpool Drug Interactions, and Toronto General Hospital Drug Interaction Tables), a study comparing the use of these resources for ART interactions yielded inconsistent results. 27 Hence, active involvement by a pharmacist to thoroughly review complicated cases of ART-related drug interactions is preferred and has been shown to improve ART adherence and outcomes. 28 …”

Section: Components Of Carementioning

confidence: 99%

Treatment Regimens and Care Models for Older Patients Living with HIV: Are We Doing Enough?

Frey¹,

Johnston²,

Siegler³

2023

HIV

View full text Add to dashboard Cite

With improved access to antiretroviral therapy throughout the world, people are aging with HIV, and a large portion of the global population of people with HIV (PWH) is now age 50 or older. Older PWH experience more comorbidities, aging-related syndromes, mental health challenges, and difficulties accessing fundamental needs than the population of older adults without HIV. As a result, ensuring that older PWH are receiving comprehensive healthcare can often be overwhelming for both PWH and the providers. Although there is a growing literature addressing the needs of this population, gaps remain in care delivery and research. In this paper, we suggest seven key components to any healthcare program designed to address the needs of older people with HIV: management of HIV, comorbidity screening and treatment, primary care coordination and planning, attention to aging related-syndromes, optimization of functional status, support of behavioral health, and improved access to basic needs and services. We review many of the difficulties and controversies related to the implementation of these components, which include the absence of screening guidelines for this population and the challenges of care integration, and we suggest key next steps.

show abstract

Antiretroviral drug–drug interactions: A comparison of online drug interaction databases

Cited by 8 publications

References 21 publications

Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study

Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study

Tertiary drug information sources for treatment and prevention of COVID-19

Treatment Regimens and Care Models for Older Patients Living with HIV: Are We Doing Enough?

Contact Info

Product

Resources

About